The Cell and Gene Therapy CROs Market is anticipated to grow at an annualized rate of 18% by 2035, according to a market research report by Roots Analysis

Characterized by high prevalence rate of rare and genetic disorders, and rise in demand for effective novel ATMPs, the cell and gene therapy contract research industry is likely to witness evolutionary advancements, in the coming years

LONDON, Sept. 14, 2023 /PRNewswire/ — Roots Analysis has announced the addition of “Cell and Gene Therapy CROs Market, 2022-2035” report to its list of offerings.

Due to the upsurge in the research and development related to genetic engineering, there has been a considerable increase in the development of cell and gene therapies. Consequently, there has been a parallel rise in outsourcing of services as more clinical studies are anticipated to start. Specifically, cell and gene therapy companies have made significant investments to support the development / adoption of advanced tools, technologies and platforms, to generate more robust and evidence based clinical data, which is required for gaining the marketing authorizations across different geographies. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. Further, CROs are believed to play a significant role in the successful approval of these drugs in a highly evolving regulatory environment. Since 2005, over 40 CROs have been established in this domain. It is worth mentioning that cell and gene therapy CROs are bolstering their existing capabilities to offer a wide range of services to their clients.

To order this 330+ page report, which features 150+ figures and 150+ tables, please visit https://www.rootsanalysis.com/reports/cell-and-gene-therapy-cros-market/230.html 

Key Market Insights

• More than 105 CROs claim to provide a wide range of preclinical and clinical services for the development of advanced therapy medicinal products.
• The current market landscape features the presence of established and emerging players, majority of the service providers offer research and analytical services for both cell and gene therapies at different scales of operation.
• Around 1,330 cell and gene therapy focused clinical trials have been registered across the globe; most of the trials are focused on evaluating therapy candidates for the treatment of various oncological indications
• In pursuit of a competitive edge and to eventually establish themselves as one-stop shops, stakeholders have actively entered into mutually beneficial partnerships
• We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings
• Our proprietary analysis highlights several potential acquisition partners for cell and gene therapy service providers across different geographies
• Our proprietary total cost of ownership model provides an informed estimate of direct and indirect expenses for setting up a contract research facility in different regions, over a span of 20 years
• The market is expected to grow at a CAGR of over 21% in the coming decade; the opportunity is likely to be well distributed across areas of expertise, therapeutic areas, scales of operation and key geographical regions

For additional details, please visit https://www.rootsanalysis.com/reports/cell-and-gene-therapy-cros-market/230.html 

The financial opportunity within the cell and gene therapy CROs market has been analyzed across the following segments:

• Area of Expertise
  – Cell Therapy
  – Gene Therapy

• Scale of Operation
  – Preclinical
  – Clinical
  – Drug Discovery

• Therapeutic Area
  – Oncological Disorders
  – Neurological Disorders
  – Cardiovascular Disorders
  – Infectious Diseases
  – Metabolic Disorders
  – Autoimmune Disorders
  – Blood Disorders
  – Rare / Genetic Disorders
  – Ophthalmic Disorders
  – Other disorders

• Analysis by Geographical Regions
  – North America
  – Europe
  – Asia Pacific
  – Latin America
  – Middle East and North Africa

The report includes profiles of key players (listed below) engaged in the offering CRO services for cell and gene therapies, across both preclinical and clinical scales of operation; each profile features a brief overview of the company, along with details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook.

•  Altasciences
•  Allucent
• Charles River Laboratories
• Creative Biolabs
• IQVIA
• Medpace 
• PPD
• Precision for Medicine
• QPS
• Accelera
• Evotec
• ICON
• Syneos Health
• CMIC Group
•  Labcorp

Key Questions Answered

•  Who are the leading players engaged in offering cell and gene therapy related research services?
•  Which business models are most commonly adopted by biopharmaceutical developers for outsourcing cell and gene therapies?
•  Which partnership models are commonly adopted by stakeholders engaged in this industry?
•  What are the key value drivers of the merger and acquisition activity in the cell and gene therapy market?
•  Which players are likely to partner with cell and gene therapy CROs?
•  Which regions emerged as the key hubs for carrying out clinical studies focused on cell and gene therapies?
•  How is the current and future market opportunity likely to be distributed across key market segments?
•  What are the anticipated future trends related to cell and gene therapy related research services?

Table of Contents

1. Preface
2. Executive Summary
3. Introduction
4. Guide To Outsourcing
5. Market Landscape
6. Company Profiles
7. Competitive Benchmarking
8. Partnerships And Collaborations
9. Mergers and Acquisitions
10. Key Acquisition Targets
11. Likely Partner Analysis for Cell Therapy CROs
12. Likely Partner Analysis for Gene Therapy CROs
13. Clinical Trial Analysis
14. Total Cost of Ownership for Cell and Gene Therapy Contract Research Organizations
15. Market Forecast and Opportunity Analysis
16. Swot Analysis
17. Conclusion
18. Interview And Survey Transcripts
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies and Organizations

For additional details, please visit https://www.rootsanalysis.com/reports/cell-and-gene-therapy-cros-market/230.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.  Gene Therapy Market: (5th Edition) Industry Trends and Global Forecasts, 2022-2035
2.  RNA Sequencing Services Market: Industry Trends and Global Forecasts, 2022-2035
3.  Global T-Cell (CAR-T, TCR, and TIL) Therapy Market: (6th Edition), Industry Trends and Global Forecasts, 2022-2035

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
gaurav.chaudhary@rootsanalysis.com

Logo – https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/the-cell-and-gene-therapy-cros-market-is-anticipated-to-grow-at-an-annualized-rate-of-18-by-2035-according-to-a-market-research-report-by-roots-analysis-301925247.html

Read the orginal article: undefined